| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-978
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2020-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102346174-B1 |
| titleOfInvention |
Method for providing the information for selecting the drugs for treating EML4-ALK positive non-small cell lung cancer and compositions for treating non-small cell lung cancer resistant to ALK inhibitors |
| abstract |
The present invention relates to a method for providing information for selecting a therapeutic agent for EML4-ALK-positive non-small cell lung cancer patients and a composition for treating ALK inhibitor-resistant non-small cell lung cancer. A method for providing information for selecting a treatment drug for EML4-ALK-positive non-small cell lung cancer patients, comprising measuring the expression level and methylation level, and a deoxycytidine analog or a pharmaceutically acceptable salt thereof as an active ingredient It relates to a composition for treating non-small cell lung cancer that has acquired resistance to an ALK inhibitor. |
| priorityDate |
2020-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |